Trade Summary

1 week ago, Bashan Dror, serving as Pres, CEO at Protalix Biotherapeutics, Inc. (PLX), purchased 56,000 shares at $1.81 per share, for a total transaction value of $101,360.00. Following this transaction, Bashan Dror now holds 2,532,934 shares of PLX.

This purchase represents a 2.00% increase in Bashan Dror's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, December 19, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, December 23, 2025, 4 days after the trade was made.

Protalix Biotherapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.